Summary
F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian ca
Platinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we have a problem with
Analysis
it's a well known fact that it's easier to help an effective therapy than an uneffective one. I have seen many attempts at re-establishing platinum sensitivity in oavarian cancer, fail. I have worked on the trials personally, as I have a personal interest in mechanisms of resistance and overcoming it. I think the real problem in ovarian cancer, is the platinum resistant. These obviously exist in two forms, the denovo resistant and the delayed. The latter are often artificially defined in clinical trials, based on how soon after the completed their last platinum treatment, they recurred, so reader beware! Never-the-less I feel we need more treatments for refractory ovarian cancer, unfortunately the FDA does not always think so( sorry Yondelis).
Donald Fleming consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
